

with HTLV-I to onset of ATL is very long in both sexes. If the latency period is equal to the mean age at onset of ATL, the mean life expectancy in females of 80.5 years in Japan in 1985 [5] is much smaller than the age (30 years or more) at which a rising number of female HTLV-I carriers, due to seroconversion via sexual transmission, occurs plus the mean age at onset (55.8 years) [4] of ATL among females. No bimodal age distribution for onset of ATL among females was reported. Therefore, the number of ATL cases among female HTLV-I carriers sexually infected from male partners is small, if any.

The risk of ATL among HTLV-I carriers horizontally infected via transfusion, irrespective of gender, is not known. A blood bank system has only been in operation in Japan for about 40 years. If the latency period is unrelated to infection route, onset of ATL among virus carriers infected via transfusion would not have occurred.

1. Takatsuki K. Adult T-cell leukemia/lymphoma. *Hematol Rev* 1990, 3, 201–209.
2. Hino S. ATL development after adult infection of HTLV-1? *Jpn J Cancer Res* 1989, 80, 1016.
3. Tokudome S, Tokunaga O, Shimamoto Y, *et al.* Incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type I carriers in Saga, Japan. *Cancer Res* 1989, 49, 226–228.
4. Okamoto T, Ohno Y, Tsugane S, *et al.* Multi-step carcinogenesis model for adult T-cell leukemia. *Jpn J Cancer Res* 1989, 80, 191–195.
5. Health and Welfare Statistics Association. *Kokumin Eisei no Doukou*. Tokyo, Health and Welfare Statistics Association, 1989, 80.

Eur J Cancer, Vol. 26, No. 11/12, p. 1262, 1990.
Printed in Great Britain
0277-5379/90 \$3.00 + 0.00
© 1990 Pergamon Press plc

Toxic Epidermal Necrolysis during Chlorambucil Therapy in Chronic Lymphocytic Leukaemia

C. Barone, A. Cassano and A. Astone

WE REPORT a 57-year-old female with chronic lymphocytic leukaemia who had toxic epidermal necrolysis (TEN) after chlorambucil alone (0.1 mg/kg per day). During initial treatment a confluent maculopapular erythema of trunk, legs, feet and mucous membranes erupted followed by large flaccid blisters and fever. Despite administration of 6-methylprednisolone the rash became widespread and exfoliation occurred. After 18 days of chlorambucil therapy, white blood cell (WBC) count was $21 \times 10^9/l$ and gram-negative sepsis had developed; therefore chlorambucil was discontinued. Erythromycin and gentamicin were started and the eruption and sepsis resolved after 8 days. The patient was discharged without further treatment (WBC $5 \times 10^9/l$).

4 months later, the patient's WBC rose to $30 \times 10^9/l$ and chlorambucil alone was restarted. No other drugs (particularly allopurinol) were used to minimise the risk of cutaneous reaction.

Correspondence to C. Barone.

The authors are at the Institute of Clinical Medicine, Catholic University of the Sacred Heart, Largo A. Gemelli 8, Rome, Italy.

A few hours after chlorambucil (2.5 mg) was taken, the patient had a diffuse erythema of the skin with eruption of flaccid blisters on buttocks and thighs. During the following days large sheets of necrotic superficial epidermis detached from the skin. A cutaneous biopsy showed coagulative necrosis of keratinocytes, dermoepidermal separation and perivascular lymphocytic infiltration. Marked sensitivity to chlorambucil caused TEN. Prompt therapy with prednisone resolved the toxic reaction.

2 months after this episode, the patient had a skin-patch test. Chlorambucil in vaseline (5 and 10%) was applied on the intact skin of the forearm (Dermo-test Diagent). A papular vesicular eruption occurred after 48 h with a maximum at 72 h. Patch tests performed with European Standard Series were negative. 10 volunteers, 5 previously treated with chlorambucil, had the same test without developing a reaction.

Chlorambucil has been associated with a cutaneous reaction in only a few cases [1–4], and our report of TEN is rare. The pathogenesis of TEN is unclear: besides immunological causes, cytochemical and photosensitivity mechanisms seem to play a role.

1. Knisley RE, Settipane GA, Albala MM. Unusual reaction to chlorambucil in a patient with chronic lymphocytic leukemia. *Arch Dermatol* 1971, 104, 77–79.
2. Millar LG, Rajah SM. Cutaneous reaction to chlorambucil. *Arch Dermatol* 1977, 113, 1298.
3. Peterman A, Braunstein B. Cutaneous reaction to chlorambucil therapy. *Arch Dermatol* 1986, 122, 1358–1360.
4. Hitchins RN, Hocker GA, Thomson DB. Chlorambucil allergy—A series of three cases. *Aust NZ J Med* 1987, 17, 600–602.

Eur J Cancer, Vol. 26, No. 11/12, pp. 1262–1263, 1990.
Printed in Great Britain
0277-5379/90 \$3.00 + 0.00
© 1990 Pergamon Press plc

Neoadjuvant Low-dose Chemotherapy with Insulin in Breast Carcinomas

Steven G. Ayre, Donato Perez Garcia y Bellon and Donato Perez Garcia Jr

WE HAVE developed a neoadjuvant chemohormonal therapy for breast carcinomas without surgery or radiotherapy. Cyclophosphamide, methotrexate and 5-fluorouracil are administered, with insulin as a biological response modifier to potentiate anticancer drug effects [1]. This regimen affords maximum breast conservation and minimum patient discomfort.

Breast malignancies are histologically verified by fine needle biopsy. Insulin/chemotherapy cycles are repeated twice a week for 3 weeks, and then weekly for another 3–6 weeks depending on clinical findings. Fasting subjects receive insulin (0.3 U/kg) and, at onset of hypoglycaemia, cyclophosphamide 8 mg/m²,

Correspondence to S.G. Ayre, 483, First Street, Antioch, IL 60002, U.S.A.

S.G. Ayre is at the Department of Family Medicine, University of Health Sciences/The Chicago Medical School, North Chicago, Illinois, U.S.A.; and D. Perez Garcia y Bellon and D. Perez Garcia Jr are at the Centro Medical Dalinde, Tuxpan, Mexico.

methotrexate 3 mg/m² and 5-fluorouracil 50 mg/m² with 50% hypertonic glucose, intravenously. On non-treatment days, patients are given oral cyclophosphamide 50 mg and methotrexate 2.5 mg.

A 32-year-old woman found a lump in her right breast in November 1988. Xeromammography confirmed the presence of a lesion (Fig. 1), and a biopsy revealed an infiltrating ductal adenocarcinoma. After 8 weeks of chemohormonal therapy, the breast mass was no longer palpable. A xeromammogram at 3 months showed no evidence of tumour (Fig. 1).

Insulin and insulin-like growth factor-1 (IGF-1) have been identified as autocrine and/or paracrine growth factors in human breast cancer cells [2–4]. We administer pharmacological doses of insulin to manipulate membrane and metabolic activities of these endogenous growth-promoting mechanisms, thereby potentiating anticancer drug effects. Drug potentiation results from an insulin-induced increase in the transmembrane passage of anticancer drugs in human breast cancer cells [5, 6], and a recruitment of cell populations into S-phase of the replicative cycle by cross-reaction of insulin with IGF-1 receptors [7]. The cell-killing effects of anticancer drugs, particularly the chemotherapy agents specific for cell cycle phase, are greatly augmented [8]. Therefore, ideal pharmacokinetic circumstances for the chemotherapy of breast cancer are created. As well as improved efficacy, this regimen increases safety because of lower total doses administered and reduced side-effects.



Fig. 1. Patient 1: xeromammogram on 3 February (left) and 15 June (right) 1989.

Chemohormonal therapy with oestrogen has shown promising results in preliminary trials [9]. However, insulin and chemotherapy is more efficacious, as not only can insulin mimic oestrogen's cell-recruiting effects in oestrogen receptor positive human breast cancer cells [10], but insulin can stimulate recruitment in oestrogen receptor negative cells as well. Also, unlike oestrogen, insulin increases the transmembrane passage and intracellular accumulation of anticancer drugs. The administration of low-dose anticancer drug therapy with insulin can produce complete and long-term regression of tumour masses in treated subjects. Therapy is tolerated without adverse effect and in our case produced excellent cosmetic results.

1. Ayre SG, Perez Garcia y Bellon D, Perez Garcia D Jr. Insulin potentiation therapy: a new concept in the management of chronic degenerative disease. *Med Hypotheses* 1986, **20**, 199–210.
2. Hilf R. The actions of insulin as a hormonal factor in breast cancer. In: Pike MC, Siiteri PK, Welsch CW, eds. *Hormones and Breast Cancer*. Cold Spring Harbor, Cold Spring Harbor Laboratory, 1981, 317–337.
3. Lippman ME, Dickson RB, Kasid A, et al. Autocrine and paracrine growth regulation of human breast cancer. *J Steroid Biochem* 1986, **24**, 147–154.
4. Cullen JK, Yee D, Sly WS, et al. Insulin-like growth factor receptor expression and function in human breast cancer. *Cancer Res* 1990, **50**, 48–53.
5. Alabaster O, Vonderhaar BK, Shafie SM. Metabolic modification by insulin enhances methotrexate cytotoxicity in MCF-7 human breast cancer cells. *Eur J Cancer Clin Oncol* 1981, **17**, 1223–1228.
6. Oster JB, Creasey WA. Enhancement of cellular uptake of ellipticine by insulin preincubation. *Eur J Cancer Clin Oncol* 1981, **17**, 1097–1103.
7. Van Wyk JJ, Graves DC, Casella SJ, Jacobs S. Evidence from monoclonal antibody studies that insulin stimulates deoxyribonucleic acid synthesis through the type 1 somatomedin receptor. *J Clin Endocrinol Metab* 1985, **61**, 639–643.
8. Shackney SE. Cell kinetics and cancer chemotherapy. In: Calabresi P, Schein PS, Rosenberg SA, eds. *Medical Oncology: Basic Principles and Clinical Management of Cancer*. New York, Macmillan, 1985, 41–60.
9. Paridaens R, Klijn JGM, Julien JP, et al. Chemotherapy with estrogenic recruitment in breast cancer: experimental background and clinical studies conducted by the EORTC breast cancer cooperative group. *Eur J Cancer Clin Oncol* 1986, **22**, 728.
10. Van der Burg B, de Laat SW, van Zoelen EJJ. Mitogenic stimulation of human breast cancer cells in a growth-factor defined medium: synergistic action of insulin and estrogens. In: Bresciani F, King RJB, Lippman ME, Raynaud JP, eds. *Progress in Cancer Research and Therapy*, vol. 35: *Hormones and Cancer* 3. New York, Raven Press, 1988, 231–233.